Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise

by fernando | Apr 9, 2026 | Media Coverage

Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer

by fernando | Feb 24, 2026 | Media Coverage

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

by fernando | Jan 6, 2026 | Media Coverage

Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer

by fernando | Dec 18, 2025 | Media Coverage

Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic

by Cartography | Oct 3, 2025 | Media Coverage

Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team

by Cartography | Sep 3, 2025 | Media Coverage